A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Purpose and Mission Founded in 1992, Anika Therapeutics, Inc. (“Anika” or “Company”) is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The Company leverages proprietary hyaluronic acid (“HA”) technology to develop highly differentiated products. Driven by strong partnerships with physicians, Anika is dedicated to pioneering HA-based innovations that redefine orthopedic care. Our mission is to restore active living, empower surgeon choice, and enhance patient outcomes worldwide. Anika’s Mission: “Together, we restore active living and redefine what’s possible with hyaluronic acid.” Anika’s Core Values: Trust and Respect: We build trust and show respect in every interaction. Quality: We are committed to quality as we work to improve people’s lives. Empowerment & Teamwork: We are empowered as a team to make decisions that drive impact. Focus: We focus on what matters most and are driven to be better every day.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 113M | 113M | 120M | 121M | 114M | 148M |
| Net Income | -11M | -11M | -56M | -83M | -15M | 4.1M |
| EPS | $-0.76 | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 |
| Free Cash Flow | 4.4M | 4.4M | -2.3M | -7.2M | -3.1M | 3.3M |
| ROIC | -10.2% | -7.3% | -6.8% | -38.9% | -5.2% | 1.4% |
| Gross Margin | 56.6% | 56.6% | 63.4% | 68.3% | 64.3% | 56.1% |
| Debt/Equity | 0.00 | 0.33 | 0.32 | 0.27 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -11M | -11M | -5.1M | -88M | -19M | 2.6M |
| Operating Margin | -9.8% | -9.8% | -4.3% | -72.6% | -17.0% | 1.8% |
| ROE | -7.6% | -7.3% | -36.6% | -38.9% | -5.2% | 1.5% |
| Shares Outstanding | 14M | 14M | 15M | 15M | 15M | 15M |
Anika Therapeutics, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 47.0x vs a median of 28.3x. The company's 5-year average gross margin is 61.7%. Total shareholder yield (buybacks) is 4.3%. At current prices, the estimated annualized return to fair value is -42.8%.
Anika Therapeutics, Inc. (ANIK) has a 5-year average return on invested capital (ROIC) of -11.4%. This is below average and may indicate limited pricing power.
Anika Therapeutics, Inc. (ANIK) has a market capitalization of $219M. It is classified as a small-cap stock.
Anika Therapeutics, Inc. (ANIK) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 4.33%.
Anika Therapeutics, Inc. (ANIK) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Anika Therapeutics, Inc. (ANIK) reported annual revenue of $113 million in its most recent fiscal year, based on SEC EDGAR filings.
Anika Therapeutics, Inc. (ANIK) has a net profit margin of -9.6%. The company is currently unprofitable.
Anika Therapeutics, Inc. (ANIK) generated $4 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Anika Therapeutics, Inc. (ANIK) has a debt-to-equity ratio of 0.33. This indicates a conservatively financed balance sheet.
Anika Therapeutics, Inc. (ANIK) reported earnings per share (EPS) of $-0.76 in its most recent fiscal year.
Anika Therapeutics, Inc. (ANIK) has a return on equity (ROE) of -7.3%. A negative ROE may indicate losses or negative equity.
Anika Therapeutics, Inc. (ANIK) has a 5-year average gross margin of 61.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for Anika Therapeutics, Inc. (ANIK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Anika Therapeutics, Inc. (ANIK) has a book value per share of $10.02, based on its most recent annual SEC filing.